Deutsche Bank’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $723K | Buy |
160,740
+20,542
| +15% | +$89.8K | ﹤0.01% | 2370 |
|
|
2025
Q4 | $674K | Buy |
140,198
+8,374
| +6% | +$37.7K | ﹤0.01% | 2404 |
|
|
2025
Q3 | $598K | Buy |
131,824
+18,118
| +16% | +$66.5K | ﹤0.01% | 2456 |
|
|
2025
Q2 | $351K | Sell |
113,706
-33,157
| -23% | -$110K | ﹤0.01% | 2636 |
|
|
2025
Q1 | $513K | Sell |
146,863
-24,903
| -14% | -$83K | ﹤0.01% | 2484 |
|
|
2024
Q4 | $562K | Buy |
171,766
+75,212
| +78% | +$277K | ﹤0.01% | 2548 |
|
|
2024
Q3 | $372K | Buy |
96,554
+23,759
| +33% | +$91.1K | ﹤0.01% | 2619 |
|
|
2024
Q2 | $225K | Sell |
72,795
-63
| -0.1% | -$189 | ﹤0.01% | 2739 |
|
|
2024
Q1 | $188K | Buy |
72,858
+6,314
| +9% | +$16.4K | ﹤0.01% | 2851 |
|
|
2023
Q4 | $166K | Sell |
66,544
-2,804
| -4% | -$5.49K | ﹤0.01% | 2974 |
|
|
2023
Q3 | $141K | Buy |
69,348
+13,838
| +25% | +$29K | ﹤0.01% | 2996 |
|
|
2023
Q2 | $128K | Sell |
55,510
-16,447
| -23% | -$42.8K | ﹤0.01% | 3148 |
|
|
2023
Q1 | $218K | Buy |
71,957
+21,696
| +43% | +$61.2K | ﹤0.01% | 2960 |
|
|
2022
Q4 | $117K | Buy |
50,261
+720
| +1% | +$1.72K | ﹤0.01% | 3256 |
|
|
2022
Q3 | $94K | Sell |
49,541
-7,217
| -13% | -$17K | ﹤0.01% | 3340 |
|
|
2022
Q2 | $154K | Buy |
56,758
+13,204
| +30% | +$33.8K | ﹤0.01% | 3308 |
|
|
2022
Q1 | $130K | Sell |
43,554
-5,246
| -11% | -$16.1K | ﹤0.01% | 3477 |
|
|
2021
Q4 | $190K | Buy |
48,800
+2,584
| +6% | +$10K | ﹤0.01% | 3411 |
|
|
2021
Q3 | $198K | Sell |
46,216
-329,537
| -88% | -$1.1M | ﹤0.01% | 3572 |
|
|
2021
Q2 | $1.14M | Buy |
375,753
+323,186
| +615% | +$1M | ﹤0.01% | 2684 |
|
|
2021
Q1 | $175K | Buy |
+52,567
| New | +$203K | ﹤0.01% | 3706 |
|
|
2020
Q4 | – | Sell |
-127,785
| Closed | -$400K | – | 4398 |
|
|
2020
Q3 | $400K | Buy |
+127,785
| New | +$389K | ﹤0.01% | 2793 |
|
|
2020
Q1 | – | Sell |
-1,742
| Closed | -$4K | – | 4287 |
|
|
2019
Q4 | $4K | Sell |
1,742
-13,070
| -88% | -$21.1K | ﹤0.01% | 4691 |
|
|
2019
Q3 | $22K | Sell |
14,812
-58,195
| -80% | -$100K | ﹤0.01% | 4283 |
|
|
2019
Q2 | $150K | Sell |
73,007
-58,147
| -44% | -$149K | ﹤0.01% | 3993 |
|
|
2019
Q1 | $468K | Buy |
131,154
+20
| +0% | +$77 | ﹤0.01% | 3491 |
|
|
2018
Q4 | $501K | Sell |
131,134
-31,471
| -19% | -$155K | ﹤0.01% | 3324 |
|
|
2018
Q3 | $1.54M | Buy |
162,605
+57,731
| +55% | +$573K | ﹤0.01% | 3016 |
|
|
2018
Q2 | $765K | Buy |
104,874
+39,961
| +62% | +$238K | ﹤0.01% | 3609 |
|
|
2018
Q1 | $324K | Sell |
64,913
-98,538
| -60% | -$522K | ﹤0.01% | 3949 |
|
|
2017
Q4 | $825K | Buy |
163,451
+32,451
| +25% | +$190K | ﹤0.01% | 3324 |
|
|
2017
Q3 | $811K | Sell |
131,000
-50,938
| -28% | -$218K | ﹤0.01% | 3158 |
|
|
2017
Q2 | $653K | Buy |
181,938
+47,233
| +35% | +$162K | ﹤0.01% | 3291 |
|
|
2017
Q1 | $436K | Buy |
134,705
+45,026
| +50% | +$125K | ﹤0.01% | 3161 |
|
|
2016
Q4 | $219K | Sell |
89,679
-111,531
| -55% | -$325K | ﹤0.01% | 3624 |
|
|
2016
Q3 | $690K | Buy |
201,210
+14,217
| +8% | +$55.5K | ﹤0.01% | 3042 |
|
|
2016
Q2 | $650K | Buy |
186,993
+99,920
| +115% | +$423K | ﹤0.01% | 3140 |
|
|
2016
Q1 | $358K | Sell |
87,073
-96,441
| -53% | -$345K | ﹤0.01% | 3381 |
|
|
2015
Q4 | $816K | Buy |
183,514
+31,114
| +20% | +$171K | ﹤0.01% | 3010 |
|
|
2015
Q3 | $927K | Buy |
152,400
+109,300
| +254% | +$969K | ﹤0.01% | 3003 |
|
|
2015
Q2 | $510K | Buy |
43,100
+800
| +2% | +$12.2K | ﹤0.01% | 3383 |
|
|
2015
Q1 | $738K | Sell |
42,300
-51,416
| -55% | -$1.05M | ﹤0.01% | 3073 |
|
|
2014
Q4 | $1.42M | Buy |
93,716
+47,616
| +103% | +$822K | ﹤0.01% | 2943 |
|
|
2014
Q3 | $974K | Sell |
46,100
-7,146
| -13% | -$117K | ﹤0.01% | 3051 |
|
|
2014
Q2 | $695K | Sell |
53,246
-14,054
| -21% | -$199K | ﹤0.01% | 3235 |
|
|
2014
Q1 | $1.45M | Buy |
67,300
+15,400
| +30% | +$277K | ﹤0.01% | 2612 |
|
|
2013
Q4 | $412K | Buy |
51,900
+5,900
| +13% | +$49.1K | ﹤0.01% | 3236 |
|
|
2013
Q3 | $319K | Buy |
+46,000
| New | +$253K | ﹤0.01% | 3817 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Deutsche Bank's ABUS Position: Q1 2026 in Review
Deutsche Bank increased its Arbutus Biopharma (ABUS) stake by 15% in Q1 2026, buying an estimated $89.8K and bringing the position to 160,740 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.
Deutsche Bank first reported a position in ABUS in Q3 2013 and has held it in 48 quarters since. The position peaked at $1.54M in Q3 2018. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Deutsche Bank held 160,740 shares of Arbutus Biopharma worth $723K as of Q1 2026.
- Deutsche Bank bought 20,542 Arbutus Biopharma shares in Q1 2026, an estimated $89.8K.
- Arbutus Biopharma made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2370 holding.
- Deutsche Bank first reported a position in Arbutus Biopharma in Q3 2013 and has held it in 48 quarters since.
- Deutsche Bank's Arbutus Biopharma position peaked at $1.54M in Q3 2018.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.